Andrew Foxley

2.5k total citations
20 papers, 385 citations indexed

About

Andrew Foxley is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Andrew Foxley has authored 20 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Andrew Foxley's work include Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (9 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Andrew Foxley is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (9 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Andrew Foxley collaborates with scholars based in United Kingdom, United States and Japan. Andrew Foxley's co-authors include Sacha J. Howell, Chris Twelves, Angela Casbard, Simon Waters, Pavel Bezecny, Rachel Butler, Robert H. Jones, Ramachandran Venkitaraman, Margherita Carucci and C. Bale and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Andrew Foxley

20 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Foxley United Kingdom	8	275	211	192	112	54	20	385
Qiufan Zheng China	11	139 0.5×	189 0.9×	153 0.8×	111 1.0×	23 0.4×	38	353
Bharani Dharan United States	6	120 0.4×	144 0.7×	152 0.8×	59 0.5×	38 0.7×	10	324
Kristi Gramlich United States	3	274 1.0×	320 1.5×	111 0.6×	55 0.5×	80 1.5×	4	386
Laura Schubert United States	6	282 1.0×	199 0.9×	198 1.0×	156 1.4×	11 0.2×	13	397
Pavel Bezecny United Kingdom	5	200 0.7×	176 0.8×	213 1.1×	102 0.9×	80 1.5×	8	371
Bishoy Khalil Canada	8	233 0.8×	82 0.4×	323 1.7×	219 2.0×	36 0.7×	8	455
Agnes Lteif United States	7	195 0.7×	182 0.9×	97 0.5×	102 0.9×	58 1.1×	16	300
Cath Trigwell United Kingdom	6	136 0.5×	150 0.7×	220 1.1×	52 0.5×	53 1.0×	9	365
Anton Safonov United States	7	134 0.5×	321 1.5×	127 0.7×	135 1.2×	23 0.4×	36	451
Elshad Hasanov United States	10	157 0.6×	105 0.5×	171 0.9×	109 1.0×	21 0.4×	36	323

Countries citing papers authored by Andrew Foxley

Since Specialization

Citations

This map shows the geographic impact of Andrew Foxley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Foxley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Foxley more than expected).

Fields of papers citing papers by Andrew Foxley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Foxley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Foxley. The network helps show where Andrew Foxley may publish in the future.

Co-authorship network of co-authors of Andrew Foxley

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Foxley. A scholar is included among the top collaborators of Andrew Foxley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Foxley. Andrew Foxley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmid, Peter, Heather L. McArthur, Baojun Xu, et al.. (2024). LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial. Annals of Oncology. 35. S1212–S1213. 5 indexed citations

Oliveira, Mafalda, H. S. Rugo, Sacha J. Howell, et al.. (2023). 187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial. ESMO Open. 8(1). 101376–101376. 5 indexed citations

Flood, Emuella, Stella Karantzoulis, Julie Bailey, et al.. (2023). Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer. PLoS ONE. 18(1). e0280259–e0280259. 2 indexed citations

Turner, Nicholas C., Mafalda Oliveira, Sacha J. Howell, et al.. (2023). Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial. Cancer Research. 83(5_Supplement). GS3–4. 23 indexed citations

Crabb, Simon J., Dingwei Ye, Hirotsugu Uemura, et al.. (2023). CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). TPS287–TPS287. 9 indexed citations

Howell, Sacha J., Angela Casbard, Margherita Carucci, et al.. (2022). Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology. 23(7). 851–864. 87 indexed citations

Lim, Jhin Jieh, Sanjay Raghav, Alvin Wong, et al.. (2022). 458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC). Annals of Oncology. 33. S748–S748. 1 indexed citations

Jones, Robert H., Angela Casbard, Margherita Carucci, et al.. (2022). Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.. Journal of Clinical Oncology. 40(16_suppl). 1005–1005. 4 indexed citations

Lim, Joline S.J., Raghav Sundar, Andrew Barnabas Wong, et al.. (2021). 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC). Annals of Oncology. 32. S585–S586. 1 indexed citations

10.

Fizazi, Karim, Daniel J. George, Maria De Santis, et al.. (2021). A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).. Journal of Clinical Oncology. 39(6_suppl). TPS178–TPS178. 24 indexed citations

11.

Turner, Nicholas C., Sacha J. Howell, Komal Jhaveri, et al.. (2020). 350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291). Annals of Oncology. 31. S388–S389. 16 indexed citations

12.

Jones, Robert H., Angela Casbard, Margherita Carucci, et al.. (2020). Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology. 21(3). 345–357. 159 indexed citations

13.

Schmid, Peter, Javier Cortés, Mark E. Robson, et al.. (2020). A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).. Journal of Clinical Oncology. 38(15_suppl). TPS1109–TPS1109. 12 indexed citations

14.

Schmid, Peter, Javier Cortés, Mark E. Robson, et al.. (2020). Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290). Cancer Research. 80(4_Supplement). OT2–8. 7 indexed citations

15.

Dean, Emma, Udai Banerji, Jan H.M. Schellens, et al.. (2018). A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. Cancer Chemotherapy and Pharmacology. 81(5). 873–883. 18 indexed citations

16.

Turner, Nicholas C., Anne Armstrong, Yamil Alonso Lopez Chuken, et al.. (2017). BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Annals of Oncology. 28. v76–v76. 1 indexed citations

17.

Banerji, Udai, Emma Dean, José Alejandro Pérez Fidalgo, et al.. (2015). A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.. Journal of Clinical Oncology. 33(15_suppl). 2500–2500. 5 indexed citations

18.

Dean, Emma, Udai Banerji, Jan H.M. Schellens, et al.. (2015). Results of OAK: A phase 1, open-label, multicentre study to compare two dosage forms of AZD5363 and to explore the effect of food on the pharmacokinetic (PK) exposure, safety, and tolerability of AZD5363 in patients with advanced solid malignancies.. Journal of Clinical Oncology. 33(15_suppl). 2577–2577. 1 indexed citations

19.

Turner, Nicholas C., Mafalda Oliveira, Anne Armstrong, et al.. (2015). Abstract CT331: “BEECH”, a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s. Cancer Research. 75(15_Supplement). CT331–CT331. 2 indexed citations

20.

Elvin, Paul, Chris Womack, Karen E. Swales, et al.. (2014). Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2541–2541. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact